{
    "id": "clinical_knowledge-258",
    "question": "When teaching a patient inhaler technique, how will you ensure that a large proportion of the drug reaches the lower airways?",
    "options": {
        "A": "Ask them to take lots of small, quick breaths in before using the inhaler.",
        "B": "Ask them to breathe normally when using the inhaler.",
        "C": "Ask them to perform the procedure as quickly as they can.",
        "D": "Ask them to hold their breath at the end of the inspiration on using the inhaler."
    },
    "answer": "D",
    "predict": "Here's the step-by-step thinking and the final answer in JSON format: ```json \"step_by_step_thinking\": \"To ensure that a large proportion of the drug reaches the lower airways when teaching a patient inhaler technique, we need to consider how the device works and the anatomy of the respiratory system. The goal is to deliver the medication to the smaller airways, such as bronchioles, where it can be effective. To achieve this, we want to minimize the amount of time the patient spends in the upper airways, where the medication can be filtered out. Let's consider the options: A. Asking the patient to take lots of small, quick breaths before using the inhaler may actually increase the amount of time spent in the upper airways, which could reduce the amount of medication reaching the lower airways. C. Asking the patient to perform the procedure as quickly as possible may also increase the time spent in the upper airways, as it may lead to a faster exhalation and potentially more time spent in the upper airways. D. Asking the patient to hold their breath at the end of the inspiration may also not be effective, as it may not ensure that the medication is delivered to the lower airways during the inspiratory phase. B. Asking the patient to breathe normally when using the inhaler is the most appropriate option. This allows the patient to take a normal, relaxed breath, which helps to minimize the time spent in the upper airways and ensures that more of the medication reaches the lower airways. This is because the medication is delivered during the inspiratory phase, when the airways are more open, and the patient is taking a normal breath, which helps to minimize the amount of medication that is filtered out by the upper airways. The answer is B. Ask them to breathe normally when using the inhaler.\" \"answer_choice\": \"B\" ```",
    "snippets": [
        {
            "id": "Pediatrics_Nelson_2904",
            "title": "Pediatrics_Nelson",
            "content": "Delivering therapeutic agents to the lower respiratory tract can be accomplished by inhalation of aerosol forms of the agents via dry powder inhaler (DPI), metered dose inhaler (MDI), or nebulizer. All of these devices are designed to generate relatively small particles that can bypass the filtering action of the upper airway and deposit in the lower airways. Many factors influence drug deposition, including patient technique, device used, age of the child, and breathing pattern. Nebulizers should be used with a face mask (infants) or mouthpiece (children and teens) to minimize loss of drug to ambient air. Plastic holding chambers (spacers) are available for all ages and should always be used with MDIs. Dry powder inhalers require a single rapid deep inhalation for optimal drug delivery, which is difficult for children under 6 years of age. MDIs and nebulizers are equally effective in delivering medications only if the technique is correct, so it is important to review this frequently"
        },
        {
            "id": "InternalMed_Harrison_20164",
            "title": "InternalMed_Harrison",
            "content": "an add-on therapy, but these are less effective than LABA. In patients with severe asthma, low-dose oral theophylline is also helpful, and when there is irreversible airway narrowing, the long-acting anticholinergic tiotropium bromide may be tried. If asthma is not controlled despite the maximal recommended dose of inhaled therapy, it is important to check compliance and inhaler technique. In these patients, maintenance treatment with an OCS may be needed, and the lowest dose that maintains control should be used. Occasionally omalizumab may be tried in steroid-dependent asthmatics who are not well controlled. Once asthma is controlled, it is important to slowly decrease therapy in order to find the optimal dose to control symptoms."
        },
        {
            "id": "Pediatrics_Nelson_1798",
            "title": "Pediatrics_Nelson",
            "content": "Figure 78-3 Estimated comparative daily dosages for inhaled corticosteroids. (From National Heart Lung Blood Institute, National Asthma Education and Prevention Program: Expert panel report 3: guidelines for the diagnosis and management of asthma. Summary report 2007, NIH Publication No. 08-5846, Bethesda, MD, 2007, U.S. Department of Health and Human Services, p 49, http://www.nhlbi.nih.gov/ guidelines/asthma/asthsumm.pdf following: allergic rhinitis, wheezing with a cold, or eosino-teaching basic asthma facts, explaining the role of medica philia of greater than 4%. Atopy is the strongest predictor for tions, teaching environmental control measures, and improv wheezing continuing into persistent asthma (Table 78-4). ing patient skills in the use of spacer devices for metered dose inhalers and peak flow monitoring. Families should have an asthma management plan (Fig. 78-5) for daily care and for PREVENTION exacerbations."
        },
        {
            "id": "InternalMed_Harrison_20445",
            "title": "InternalMed_Harrison",
            "content": "Patients are often treated initially with nebulized therapy, as such 1707 treatment is often easier to administer in older patients or to those in respiratory distress. It has been shown, however, that conversion to metered-dose inhalers is effective when accompanied by education and training of patients and staff. This approach has significant economic benefits and also allows an easier transition to outpatient care. The addition of methylxanthines (such as theophylline) to this regimen can be considered, although convincing proof of its efficacy is lacking. If added, serum levels should be monitored in an attempt to minimize toxicity."
        },
        {
            "id": "InternalMed_Harrison_20165",
            "title": "InternalMed_Harrison",
            "content": "Education Patients with asthma need to understand how to use their medications and the difference between reliever and controller FIGURE 309-8 Stepwise approach to asthma therapy according to the severity of asthma and ability to control symptoms. ICS, inhaled corticosteroids; LABA, long-acting \u03b22-agonist; OCS, oral corticosteroid. therapies. Education may improve compliance, particularly with ICS. 1679 All patients should be taught how to use their inhalers correctly. In particular, they need to understand how to recognize worsening of asthma and how to step up therapy. Written action plans have been shown to reduce hospital admissions and morbidity rates in adults and children, and are recommended particularly in patients with unstable disease who have frequent exacerbations."
        },
        {
            "id": "Pediatrics_Nelson_1794",
            "title": "Pediatrics_Nelson",
            "content": "Key: DPI, Dry power inhaler; HFA, hydrofluoroalkane; MDI, metered-dose inhaler; NA, not available (either not approved, no data available, or safety and efficacy not established for this age group) Therapeutic Issues: \u007f The most important determinant of appropriate dosing is the clinician\u2019s judgment of the patient\u2019s response to therapy. The clinician must monitor the patient\u2019s response on several clinical parameters and adjust the dose accordingly. Once control of asthma is achieved, the dose should be carefully titrated to the minimum dose required to maintain control. \u007f Preparations are not interchangeable on a \u00b5g or per puff basis. This figure presents estimated comparable daily doses. See EPR\u20133 Full Report 2007 for full discussion. \u007f Some doses may be outside package labeling, especially in the high-dose range. Budesonide nebulizer suspension is the only inhaler corticosteroid (ICS) with FDAapproved labeling for children <4 years of age."
        },
        {
            "id": "Pharmacology_Katzung_2862",
            "title": "Pharmacology_Katzung",
            "content": "the patient\u2019s larynx and vocal cords and cannot successfully pass an endotracheal tube. You switch to mask ventilation but are barely able to mask ventilate the patient, and you become worried that you will soon lose the ability to ventilate at all. Is there a medication that you can give to facilitate rapid return of spontaneous ventilation in this situation?"
        },
        {
            "id": "Pediatrics_Nelson_1778",
            "title": "Pediatrics_Nelson",
            "content": "Step up if needed (first check inhaler technique, adherence, environmental control, and comorbid conditions) Step down if possible (and asthma is well controlled at least 3 months)"
        },
        {
            "id": "Pharmacology_Katzung_2047",
            "title": "Pharmacology_Katzung",
            "content": "Joshua M. Galanter, MD, & Homer A. Boushey, MD and respirations are 32/min. Her mother states that she has used her albuterol inhaler several times a day for the past 3 days and twice during the previous night. She took an additional two puffs on her way to the emergency department, but her mother states that \u201cthe inhaler didn\u2019t seem to be helping so I told her not to take any more.\u201d What emergency measures are indicated? How should her long-term management be altered? A 14-year-old girl with a history of asthma requiring daily inhaled corticosteroid therapy and allergies to house dust mites, cats, grasses, and ragweed presents to the emergency department in mid-September, reporting a recent \u201ccold\u201d com-plicated by worsening shortness of breath and audible inspi-ratory and expiratory wheezing. She appears frightened and refuses to lie down but is not cyanotic. Her pulse is 120 bpm,"
        },
        {
            "id": "InternalMed_Harrison_20168",
            "title": "InternalMed_Harrison",
            "content": "A high concentration of oxygen should be given by face mask to achieve oxygen saturation of >90%. The mainstay of treatment are high doses of SABA given either by nebulizer or via a metered-dose inhaler with a spacer. In severely ill patients with impending respiratory failure, IV \u03b22-agonists may be given. A nebulized anticholinergic may be added if there is not a satisfactory response to \u03b22-agonists alone, as there are additive effects. In patients who are refractory to inhaled therapies, a slow infusion of aminophylline may be effective, but it is important to monitor blood levels, especially if patients have already been treated with oral theophylline. Magnesium sulfate given intravenously or by nebulizer is effective when added to inhaled \u03b22-agonists, and is relatively well tolerated but is not routinely recommended. Prophylactic intubation may be indicated for impending respiratory failure, when the PCO2 is normal or rises. For patients with respiratory failure, it is necessary"
        },
        {
            "id": "InternalMed_Harrison_20423",
            "title": "InternalMed_Harrison",
            "content": "Bronchodilators In general, bronchodilators are used for symptomatic benefit in patients with COPD. The inhaled route is preferred for medication delivery because the incidence of side effects is lower than that seen with the use of parenteral medication delivery."
        },
        {
            "id": "InternalMed_Harrison_20140",
            "title": "InternalMed_Harrison",
            "content": "SAFETY The safety of \u03b22-agonists has been an important issue. There is an association between asthma mortality and the amount of SABA used, but careful analysis demonstrates that the increased use of rescue SABA reflects poor asthma control, which is a risk factor for asthma death. The slight excess in mortality that has been associated with the use of LABA is related to the lack of use of concomitant ICS, as the LABA therapy fails to suppress the underlying inflammation. This highlights the importance of always using an ICS when LABAs are given, which is most conveniently achieved by using a combination inhaler."
        },
        {
            "id": "Pharmacology_Katzung_2073",
            "title": "Pharmacology_Katzung",
            "content": "Albuterol, terbutaline, metaproterenol, and pirbuterol are available as metered-dose inhalers. Given by inhalation, these agents cause bronchodilation equivalent to that produced by isoproterenol. Bronchodilation is maximal within 15 minutes and persists for 3\u20134 hours. All can be diluted in saline for administration from a hand-held nebulizer. Because the particles generated by a nebulizer are much larger than those from a metered-dose inhaler, much higher doses must be given (2.5\u20135.0 mg vs 100\u2013 400 mcg) but are no more effective. Nebulized therapy should thus be reserved for patients unable to coordinate inhalation from a metered-dose inhaler."
        },
        {
            "id": "Pharmacology_Katzung_2137",
            "title": "Pharmacology_Katzung",
            "content": "An important caveat for patients with mild asthma is that although the risk of a severe, life-threatening attack is low, it is not zero. All patients with asthma should be instructed in a simple action plan for severe, frightening attacks: to take up to four puffs of albuterol every 20 minutes over 1 hour. If no improvement is noted after the first four puffs, additional treatments should be taken while on the way to an emergency department or other higher level of care."
        },
        {
            "id": "InternalMed_Harrison_20138",
            "title": "InternalMed_Harrison",
            "content": "because they do not control the underlying inflammation. They do, however, improve asthma control and reduce exacerbations when added to ICS, which allows asthma to be controlled at lower doses of corticosteroids. This observation has led to the widespread use of fixed-combination inhalers that contain a corticosteroid and a LABA, which have proved to be highly effective in the control of asthma."
        },
        {
            "id": "InternalMed_Harrison_24838",
            "title": "InternalMed_Harrison",
            "content": "performed once a week, although the frequency can be adjusted on a case-by-case basis. A trough level of 800 mg/mL is desirable. Whatever the mode of administration, the main goal is to reduce the frequency of the respiratory tract infections and prevent chronic lung and sinus disease. The two routes appear to be equally safe and efficacious, and so the choice should be left to the preference of the patient."
        },
        {
            "id": "InternalMed_Harrison_20170",
            "title": "InternalMed_Harrison",
            "content": "SPECIAL CONSIDERATIONS Refractory Asthma Although most patients with asthma are easily controlled with appropriate medication, a small proportion of patients (approximately 5\u201310% of asthmatics) are difficult to control despite maximal inhaled therapy. Some of these patients will require maintenance treatment with OCS. In managing these patients, it is important to investigate and correct any mechanisms that may be aggravating asthma. There are two major patterns of difficult asthma: some patients have persistent symptoms and poor lung function, despite appropriate therapy, whereas others may have normal or near-normal lung function but intermittent, severe (sometimes life-threatening) exacerbations."
        },
        {
            "id": "Pediatrics_Nelson_1806",
            "title": "Pediatrics_Nelson",
            "content": "Add: mg per day. For (3\u201310) days (oral corticosteroid) the doctor hours after taking the oral corticosteroid.(phone) Medical Alert! Take this medicine: Very short of breath, or Nebulizer Quick-relief medicines have not helped, or (short-acting beta2-agonist) Cannot do usual activities, or mg Symptoms are same or get worse after (oral corticosteroid) 24 hours in Yellow Zone. Then call your doctor NOW. Go to the hospital or call an ambulance if You are still in the red zone after 15 minutes AND Peak flow: less than You have not reached your doctor. (50 percent of my best peak flow) Trouble walking and talking due to shortness of breath puffs of your quick-relief medicine 6AND Lips or fingernails are blue Go to the hospital or call for an ambulance NOW! Allergy Atopic dermatitis Allergic rhinitis Elevated total serum IgE levels (first year of life) Peripheral blood eosinophilia >4% (2\u20133 yr of age) Food and inhalant allergen sensitization"
        },
        {
            "id": "InternalMed_Harrison_20134",
            "title": "InternalMed_Harrison",
            "content": "The treatment of asthma is straightforward, and the majority of patients are now managed by internists and family doctors with effective and safe therapies. There are several aims of therapy (Table 309-2). Most emphasis has been placed on drug therapy, but several nonpharmacologic approaches have also been used. The main drugs for asthma can be divided into bronchodilators, which give rapid relief of symptoms mainly through relaxation of airway smooth muscle, and controllers, which inhibit the underlying inflammatory process."
        },
        {
            "id": "Pediatrics_Nelson_1763",
            "title": "Pediatrics_Nelson",
            "content": "Inhaled corticosteroids are the most effective anti-inflammatory medications for the treatment of chronic, persistent asthma and are the preferred therapy when initiating longterm control therapy. Early intervention with inhaled corticosteroids reduces morbidity but does not alter the natural history of asthma. Regular use reduces airway hyperreactivity, the need for rescue bronchodilator therapy, risk of hospitalization, and risk of death from asthma. Inhaled corticosteroids are available as an inhalation aerosol, dry powder inhaler, and nebulizer solution."
        },
        {
            "id": "Pharmacology_Katzung_2166",
            "title": "Pharmacology_Katzung",
            "content": "Barnes P: How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148:245. Beasley R et al: Combination corticosteroid/beta-agonist inhaler as reliever therapy: A solution for intermittent and mild asthma? J Allergy Clin Immunol 2014;133:39. Boushey HA et al: Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519. Suissa S et al: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332. D\u2019Amato M et al: Anticholinergic drugs in asthma therapy. Curr Opin Pulm Med 2016;22:527. Lee AM, Jacoby DB, Fryer AD: Selective muscarinic receptor antagonists for airway diseases. Curr Opin Pharmacol 2001;1:223. Peters SP et al: Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715. Calhoun WJ: Anti-leukotrienes for asthma. Curr Opin Pharmacol 2001;1:230."
        },
        {
            "id": "Pharmacology_Katzung_2138",
            "title": "Pharmacology_Katzung",
            "content": "Inhaled muscarinic antagonists have so far earned a limited place in the treatment of asthma. The effects of short-acting agents (eg, ipratropium bromide) on baseline airway resistance are nearly as great as, but no greater than, those of the sympathomimetic drugs, so they are used largely as alternative therapies for patients intolerant of \u03b2-adrenoceptor agonists. The airway effects of antimuscarinic and sympathomimetic drugs given in full doses have been shown to be additive only in reducing hospitalization rates in patients with severe airflow obstruction who present for emergency care."
        },
        {
            "id": "Pharmacology_Katzung_2172",
            "title": "Pharmacology_Katzung",
            "content": "slip into respiratory failure quickly, and intubation can be difficult. Fortunately, most patients treated in hospital emergency departments do well. Asthma mortality is rare (fewer than 4000 deaths per year among a population of more than 20 million asthmatics in the USA), and when it occurs, it is often out of hospital. Presuming this patient recovers, she needs adjustments to her therapy before discharge. The strongest predictor of severe attacks of asthma is their occur-rence in the past. Thus, this patient\u2019s therapy needs to be stepped up to a higher level, like a high-dose inhaled cortico-steroid in combination with a long-acting \u03b2agonist. Both the patient and her parents need instruction on the importance of regular adherence to therapy, with reassurance that it can be \u201cstepped down\u201d to a lower dose of inhaled corticosteroid (although still in combination with a long-acting \u03b2 agonist) once her condition stabilizes. They also need instruction on an action plan for managing"
        },
        {
            "id": "Pharmacology_Katzung_2173",
            "title": "Pharmacology_Katzung",
            "content": "down\u201d to a lower dose of inhaled corticosteroid (although still in combination with a long-acting \u03b2 agonist) once her condition stabilizes. They also need instruction on an action plan for managing severe symptoms. This can be as simple as advising that if the patient has a severe, frightening attack, she can take up to four puffs of albuterol every 15 minutes, but if the first treatment does not bring significant relief, she should take the next four puffs while on her way to an emergency department or urgent care clinic. She should also be given a prescription for prednisone, with instructions to take 40\u201360 mg orally for severe attacks, but not to wait for it to take effect if she remains severely short of breath even after albuterol inhalations. Asthma is a chronic disease, and good care requires close follow-up and creation of a provider-patient partnership for optimal management. If she has had several previous exacerbations, she should be considered a candidate for monoclonal"
        },
        {
            "id": "InternalMed_Harrison_20177",
            "title": "InternalMed_Harrison",
            "content": "Refractory asthma is difficult to control, by definition. It is important to check compliance and the correct use of inhalers and to identify and eliminate any underlying triggers. Low doses of theophylline may be helpful in some patients, and theophylline withdrawal has been found to worsen in many patients. Most of these patients will require maintenance treatment with oral corticosteroids, and the minimal dose that achieves satisfactory control should be determined by careful dose titration. Steroid-sparing therapies are rarely effective. In some patients with allergic asthma, omalizumab is effective, particularly when there are frequent exacerbations. Anti-TNF therapy is not effective in severe asthma and should not be used. A few patients may benefit from infusions of \u03b22-agonists. New therapies are needed for these patients, who currently consume a disproportionate amount of health care spending."
        },
        {
            "id": "InternalMed_Harrison_20166",
            "title": "InternalMed_Harrison",
            "content": "Exacerbations of asthma are feared by patients and may be life threatening. One of the main aims of controller therapy is to prevent exacerbations; in this respect, ICS and combination inhalers are very effective."
        },
        {
            "id": "Pediatrics_Nelson_2905",
            "title": "Pediatrics_Nelson",
            "content": "is difficult for children under 6 years of age. MDIs and nebulizers are equally effective in delivering medications only if the technique is correct, so it is important to review this frequently and carefully with families."
        },
        {
            "id": "Pediatrics_Nelson_1799",
            "title": "Pediatrics_Nelson",
            "content": "PREVENTION exacerbations. Education plays an important role in helping patients and Peak flow monitoring is a self-assessment tool that is help- their families adhere to the prescribed therapy and needs to ful for children over 5 years of age. It is advisable for children begin at the time of diagnosis. Successful education involves who are poor perceivers of airway obstruction, have moderate FEV1 or PEF <40% (severe) \u007f Oxygen to achieve SaO2 \u02dc90% \u007f High-dose inhaled SABA plus Ipratropium by nebulizer or MDI plus valved holding chamber, every 20 minutes or continuously for 1 hour \u007f Oral systemic corticosteroids FEV1 or PEF \u02dc40% (mild-to-moderate) \u007f Oxygen to achieve SaO2 \u02dc90% \u007f Inhaled SABA by nebulizer or MDI with valved holding chamber, up to 3 doses in first hour \u007f Oral systemic corticosteroids if no immediate response or if patient recently took oral systemic corticosteroids"
        },
        {
            "id": "Pediatrics_Nelson_1786",
            "title": "Pediatrics_Nelson",
            "content": "Intermittent asthma Persistent asthma: Daily medication Consult with asthma specialist if Step 4 care or higher is required. Consider consultation at Step 3. Step 1 Preferred:SABA PRN Step 2 Preferred:Low-dose ICS Alternative:Cromolyn, LTRA, Nedocromil, or Theophylline Step 3 Preferred:Low-dose ICS + LABA ORMedium-dose ICS Alternative:Low-dose ICS + either LTRA, Theophylline, or Zileuton Step 4 Preferred:Medium-dose ICS + LABA Alternative:Medium-dose ICS + either LTRA, Theophylline, or Zileuton Step 5 AND Preferred:High-dose ICS + LABA Consider Omalizumab for patients who have allergies Preferred:Step 6 AND High-dose ICS + LABA + oral corticosteroid Consider Omalizumab for patients who have allergies Each step: Patient education, environmental control, and management of comorbidities. Steps 2\u20134: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma (see Notes). Quick-relief medication for all patients \u007f SABA as needed for symptoms. Intensity of treatment"
        },
        {
            "id": "InternalMed_Harrison_20163",
            "title": "InternalMed_Harrison",
            "content": "Stepwise Therapy For patients with mild, intermittent asthma, a short-acting \u03b22-agonist is all that is required (Fig. 309-8). However, use of a reliever medication more than twice a week indicates the need for regular controller therapy. The treatment of choice for all patients is an ICS given twice daily. It is usual to start with an intermediate dose (e.g., 200 \u03bcg bid of beclomethasone dipropionate [BDP]) or equivalent and to decrease the dose if symptoms are controlled after 3 months. If symptoms are not controlled, a LABA should be added, which is most conveniently given by switching to a combination inhaler. The dose of controller should be adjusted accordingly, as judged by the need for a rescue inhaler. Low doses of theophylline or an antileukotriene may also be considered as an add-on therapy, but these are less effective than LABA. In patients with severe asthma, low-dose oral theophylline is also helpful, and when there is irreversible airway narrowing, the long-acting"
        },
        {
            "id": "Pediatrics_Nelson_829",
            "title": "Pediatrics_Nelson",
            "content": "The major role of endotracheal intubation is to protect or maintain the airway and ensure the delivery of adequate oxygen to the patient. Because hypoxemia is the final common pathway in pediatric cardiopulmonary arrests, providing oxygen is more important than correcting the respiratory acidosis. The clinician should deliver 100% oxygen at a rate of 8 to 10 breaths/min during CPR, or 12 to 20 breaths/min for a patient who has a perfusing rhythm. Use only the tidal volume necessary to produce visible chest rise. Care should be taken not to hyperventilate the patient. When mechanical means fail to re-establish adequate circulation, pharmacologic intervention is essential (Table 38-4).If intravascular access is not present or rapidly established, administration through an intraosseous route is recommended. Some drugs can also be administered effectively through the endotracheal tube."
        },
        {
            "id": "InternalMed_Harrison_20137",
            "title": "InternalMed_Harrison",
            "content": "CLINICAL USE \u03b22-Agonists are usually given by inhalation to reduce side effects. Short-acting \u03b22-agonists (SABAs) such as albuterol and terbutaline have a duration of action of 3\u20136 h. They have a rapid onset of bronchodilatation and are, therefore, used as needed for symptom relief. Increased use of SABA indicates that asthma is not controlled. They are also useful in preventing EIA if taken prior to exercise. SABAs are used in high doses by nebulizer or via a metered-dose inhaler with a spacer. Long-acting \u03b22-agonists (LABAs) include salmeterol and formoterol, both of which have a duration of action over 12 h and are given twice daily by inhalation; indacaterol is given once daily. LABAs have replaced the regular use of SABAs, but LABAs should not be given in the absence of ICS therapy because they do not control the underlying inflammation. They do, however, improve asthma control and reduce exacerbations when added to ICS, which allows asthma to be controlled at lower doses of"
        }
    ],
    "scores": [
        0.03837783159120866,
        0.034652268393821344,
        0.031484327080656016,
        0.02849002849002849,
        0.027292294446835987,
        0.026894638112724738,
        0.025832058782372165,
        0.025198150153040083,
        0.025068766245236834,
        0.024419762138951293,
        0.023968322638017642,
        0.023354779465708235,
        0.022143297269738797,
        0.021841409956164057,
        0.021787584320015096,
        0.021474019088016966,
        0.021018520497013856,
        0.020752651797934552,
        0.020191147608430954,
        0.01874865380473245,
        0.0185374095225902,
        0.018404390037990714,
        0.018350930115636,
        0.017862838915470493,
        0.017304393227418516,
        0.01716769820218096,
        0.016952759256632144,
        0.01692155196828094,
        0.015407061569886197,
        0.015220189133232611,
        0.015109890109890112,
        0.014932857859252243
    ],
    "execution_time": 41.061596155166626
}